Trials / Recruiting
RecruitingNCT06994169
Glofitamab in Real Life
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- The Lymphoma Academic Research Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glofitamab | Glofitamab received for DLBCL in Early Phase Access |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-03-30
- Completion
- 2026-07-30
- First posted
- 2025-05-29
- Last updated
- 2026-01-14
Locations
30 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06994169. Inclusion in this directory is not an endorsement.